Treatment of Hypertension: an Interventional Approach to Improve Blood Pressure Control (DRIVE)
調査の概要
詳細な説明
More than 1 billion people world wide suffer from hypertension (HT), leaving it the world´s top rank risk factor and contributor to global disease burden. Cardiac disease, stroke, kidney disease and dementia are diseases related to HT with high economic burden on societies and each year 9.4 million people die as a direct consequence of HT.
Estimated < 50 % of hypertensive patients adhere to preventive hypertensive medication after 1 year of treatment.
Poor adherence to antihypertensive treatment have by many been explained partly by the silent nature of hypertension, the risk of side effects from antihypertensive medication, treatment expenditures and the patient health perspectives.
In a randomized controlled trial design we plan to enrol 20 subjects, the limited number explained by the study being part of the initial planning of a larger scale trial organized by the research group, to invistigate the change in ambulatory bloodpressure with or with out Direct Observed Theraphy prior to meassurement, as a one-time-only medication adherence check.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Oslo、ノルウェー、0407
- Oslo University Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- 18 years and above
- Residing in Oslo/Akershus
- Ambulatory Systolic Daytime Blood Pressure ≥ 135 mmHg
- ≥ 2 antihypertensive medications
- Be able to read and write Norwegian
Exclusion Criteria:
- Critical illness, ongoing treatment
- Known atrial fibrillation
- Known heart valve stenosis
- Myocardial infarction, angina pectoris or stroke the past 6 months
- Known severe renal impairment (eGFR < 30 ml/min/1.73 m2)
- History of DOT prior to ABPM
- Participation in other interventional study
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：防止
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
介入なし：コントロール
標準ケア
|
|
|
実験的：Direct Observed Therapy
Direct Observed Therapy immediately followed by mounting of ambulatory blood pressure device and measurement of ambulatory blood pressure according to ESH 2013 guidelines.
|
Patients allocated to the intervention group take their medication (from original blister packaged) in front of the invistigator who observe the patient swallowing the medication.
To secure the principals of Direct Observed Therapy, the patient do not leave the clinic for two hours.
他の名前：
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Change in 24-hour ambulatory mean systolic daytime blood pressure
時間枠：Measurement at follow-up visit 3 weeks ± 7 days relative to baseline.
|
Measurement at follow-up visit 3 weeks ± 7 days relative to baseline.
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
Change in mean office systolic blood pressure
時間枠：Measurement at follow-up visit 3 weeks ± 7 days relative to baseline.
|
Measurement at follow-up visit 3 weeks ± 7 days relative to baseline.
|
協力者と研究者
スポンサー
捜査官
- 主任研究者：Aud Høieggen, MD PhD、Oslo University Hospital
出版物と役立つリンク
一般刊行物
- Fadl Elmula FE, Hoffmann P, Fossum E, Brekke M, Gjonnaess E, Hjornholm U, Kjaer VN, Rostrup M, Kjeldsen SE, Os I, Stenehjem AE, Hoieggen A. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension. 2013 Sep;62(3):526-32. doi: 10.1161/HYPERTENSIONAHA.113.01452. Epub 2013 Jul 8.
- Fadl Elmula FE, Hoffmann P, Larstorp AC, Fossum E, Brekke M, Kjeldsen SE, Gjonnaess E, Hjornholm U, Kjaer VN, Rostrup M, Os I, Stenehjem A, Hoieggen A. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension. 2014 May;63(5):991-9. doi: 10.1161/HYPERTENSIONAHA.114.03246. Epub 2014 Mar 3.
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
Direct Observed Therapyの臨床試験
-
Northwest Biotherapeuticsわからない
-
Institute of Cancer Research, United KingdomCancer Research UK; University of Manchester; University of Sussex完了
-
Universitätsklinikum Hamburg-EppendorfCytoSorbents, Inc募集
-
Universitätsklinikum Hamburg-Eppendorf完了